Colonoscopy Prep Is Worse Than IKEA

I'm on day three of my colonoscopy preparation. You read that right. Day three. Had this been knee surgery, I would have been in and out the same day.
This is a routine colonoscopy—the kind you're supposed to get every 10 years. Last time, the preparation was minimal: Start drinking a gallon of laxative solution at 6:00 the night before the surgery and try to finish it within two hours.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

43 minutes ago

• Yahoo

New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing

Data Presented at the 2025 American Society for Microbiology Microbe Conference BOSTON, June 22, 2025--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. "This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup," said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. "This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections." The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? "These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical," said Brad Murray, chief executive officer of Delve Bio. "We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need." Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on Contacts Company Contact Amy WongSenior Director of Marketing and Business Development, Delve BioEmail: media@ Media Contact Julie McKeough42 North for Delve BioEmail: julie@ Sign in to access your portfolio

Yahoo

an hour ago

• Yahoo

Hailey Bieber Effortlessly Styled Three of Summer's Biggest Trends in One Outfit

All products featured on Glamour are independently selected by Glamour editors. However, when you buy something through our retail links, Condé Nast may earn an affiliate commission. Getty Leave it to Hailey Bieber, our undisputed Queen of Trends, to style three of this summer's most popular (and most controversial) micro-trends and make it look effortless. On June 21st, the Rhode Skin founder was photographed in New York City wearing polka dots, skinny capris, and heeled flip-flops to create the most specifically summer-of-2025 outfit ever devised by influencer or stylist. The hero piece of the outfit is clearly the white capri leggings with their oversized black polka dot pattern from Paloma Wool. Bieber has been leading the capri pants vanguard, which made a triumphant return to mainstream fashion after most of us thought they'd gone the way of the gaucho. Capris—specifically styles like this that hug the thigh and end just below the knee—last had their moment in the sun in the mid-2000s. Now, they have been embraced by everyone from Emma Stone to Bella Hadid to Meghan Markle. Polka dots are, obviously, not nearly as controversial a fashion choice as capris, but the pattern is also having a trendy moment of its own. Celebs like Sydney Sweeney and Kaia Gerber have both been seen rocking polka dot dresses recently, bringing the classic motif into the current era. Kitten heel flip-flops, however, are definitely not timeless. Like the skinny capri pants Bieber wears here, the last time heeled thong sandals were popular was the mid-aughts. But now, they are one of the summer's hottest trends, even for office-wear. We've seen heeled flip-flops like Bieber's from mid-range brands like Madewell and Reformation, as well as from more luxury labels like Toteme. Hailey Bieber completed her trend-heavy ensemble with a simple black tank, a black mini bag, narrow black sunglasses, and a single gold watch. Naturally, Bieber's look also stayed true to the barely-there pedicure trend that she herself helped to start. The only way Bieber's ensemble could be any more of-the-moment is if she had a Labubu with her. Originally Appeared on Glamour

Washington Post

2 hours ago

• Washington Post

Hall of Famer D. Wayne Lukas has been hospitalized and will not return to training, family says

LOUISVILLE, Ky. — Hall of Fame horse racing trainer D. Wayne Lukas has been hospitalized and will not return to training, Churchill Downs announced Sunday after speaking with members of his family. Lukas' family said the 89-year-old has battled a severe infection that has worsened and that he has declined an aggressive treatment plan to instead return home. His horses have been transferred to assistant trainer Sebastian 'Bas' Nicholl.